Next Article in Journal
Proteome Analysis of Human Follicular Thyroid Cancer Cells Exposed to the Random Positioning Machine
Next Article in Special Issue
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
Previous Article in Journal
Simplifying the Preparation of Pollen Grains for MALDI-TOF MS Classification
Previous Article in Special Issue
The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial–Mesenchymal Transition
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(3), 547;

Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells

Department of Pharmacy, University of Naples “Federico II”, Via Domenico Montesano 49, 80131 Naples, Italy
Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Via Sergio Pansini 5, 80131 Naples, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Li Yang
Received: 18 January 2017 / Revised: 21 February 2017 / Accepted: 1 March 2017 / Published: 3 March 2017
(This article belongs to the Special Issue Tumor Microenvironment and Metabolism)
Full-Text   |   PDF [1677 KB, uploaded 3 March 2017]   |  


Cancer is one of the most common causes of death among adults. Chemotherapy is crucial in determining patient survival and quality of life. However, the development of multidrug resistance (MDR) continues to pose a significant challenge in the management of cancer. In this study, we analyzed the role of human ribosomal protein uL3 (formerly rpL3) in multidrug resistance. Our studies revealed that uL3 is a key determinant of multidrug resistance in p53-mutated lung cancer cells by controlling the cell redox status. We established and characterized a multidrug resistant Calu-6 cell line. We found that uL3 down-regulation correlates positively with multidrug resistance. Restoration of the uL3 protein level re-sensitized the resistant cells to the drug by regulating the reactive oxygen species (ROS) levels, glutathione content, glutamate release, and cystine uptake. Chromatin immunoprecipitation experiments and luciferase assays demonstrated that uL3 coordinated the expression of stress-response genes acting as transcriptional repressors of solute carrier family 7 member 11 (xCT) and glutathione S-transferase α1 (GST-α1), independently of Nuclear factor erythroid 2-related factor 2 (Nrf2). Altogether our results describe a new function of uL3 as a regulator of oxidative stress response genes and advance our understanding of the molecular mechanisms underlying multidrug resistance in cancers. View Full-Text
Keywords: ribosomal protein; nucleolar stress; uL3; multidrug resistance; lung cancer; Nrf2; xCT; GST-α1; MDR1; chemoresistance ribosomal protein; nucleolar stress; uL3; multidrug resistance; lung cancer; Nrf2; xCT; GST-α1; MDR1; chemoresistance

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Russo, A.; Saide, A.; Smaldone, S.; Faraonio, R.; Russo, G. Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells. Int. J. Mol. Sci. 2017, 18, 547.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top